nodes	percent_of_prediction	percent_of_DWPC	metapath
Conivaptan—CYP3A4—Efavirenz—acquired immunodeficiency syndrome	0.075	0.126	CbGbCtD
Conivaptan—CYP3A4—Lopinavir—acquired immunodeficiency syndrome	0.0705	0.119	CbGbCtD
Conivaptan—CYP3A4—Nevirapine—acquired immunodeficiency syndrome	0.0705	0.119	CbGbCtD
Conivaptan—CYP3A4—Delavirdine—acquired immunodeficiency syndrome	0.0638	0.107	CbGbCtD
Conivaptan—CYP3A4—Amprenavir—acquired immunodeficiency syndrome	0.0638	0.107	CbGbCtD
Conivaptan—CYP3A4—Indinavir—acquired immunodeficiency syndrome	0.0551	0.0925	CbGbCtD
Conivaptan—CYP3A4—Nelfinavir—acquired immunodeficiency syndrome	0.0534	0.0898	CbGbCtD
Conivaptan—CYP3A4—Ritonavir—acquired immunodeficiency syndrome	0.0483	0.0812	CbGbCtD
Conivaptan—CYP3A4—Saquinavir—acquired immunodeficiency syndrome	0.0483	0.0812	CbGbCtD
Conivaptan—CYP3A4—Zidovudine—acquired immunodeficiency syndrome	0.0463	0.0779	CbGbCtD
Conivaptan—AVPR1A—Peptide GPCRs—ACKR1—acquired immunodeficiency syndrome	0.00491	0.0431	CbGpPWpGaD
Conivaptan—AVPR2—Peptide GPCRs—ACKR1—acquired immunodeficiency syndrome	0.00487	0.0427	CbGpPWpGaD
Conivaptan—AVPR1A—lung—acquired immunodeficiency syndrome	0.00431	0.155	CbGeAlD
Conivaptan—AVPR1A—central nervous system—acquired immunodeficiency syndrome	0.00384	0.138	CbGeAlD
Conivaptan—AVPR1A—Peptide ligand-binding receptors—CCL3L1—acquired immunodeficiency syndrome	0.00381	0.0334	CbGpPWpGaD
Conivaptan—AVPR2—Peptide ligand-binding receptors—CCL3L1—acquired immunodeficiency syndrome	0.00378	0.0332	CbGpPWpGaD
Conivaptan—AVPR2—lung—acquired immunodeficiency syndrome	0.00357	0.129	CbGeAlD
Conivaptan—AVPR2—nervous system—acquired immunodeficiency syndrome	0.00331	0.119	CbGeAlD
Conivaptan—AVPR2—central nervous system—acquired immunodeficiency syndrome	0.00318	0.115	CbGeAlD
Conivaptan—AVPR1A—brain—acquired immunodeficiency syndrome	0.00305	0.11	CbGeAlD
Conivaptan—AVPR1A—Peptide GPCRs—CCR2—acquired immunodeficiency syndrome	0.00274	0.0241	CbGpPWpGaD
Conivaptan—AVPR2—Peptide GPCRs—CCR2—acquired immunodeficiency syndrome	0.00272	0.0239	CbGpPWpGaD
Conivaptan—AVPR1A—Peptide GPCRs—CXCR4—acquired immunodeficiency syndrome	0.00258	0.0226	CbGpPWpGaD
Conivaptan—AVPR2—Peptide GPCRs—CXCR4—acquired immunodeficiency syndrome	0.00256	0.0225	CbGpPWpGaD
Conivaptan—AVPR1A—Class A/1 (Rhodopsin-like receptors)—CCL3L1—acquired immunodeficiency syndrome	0.00255	0.0224	CbGpPWpGaD
Conivaptan—AVPR2—Class A/1 (Rhodopsin-like receptors)—CCL3L1—acquired immunodeficiency syndrome	0.00254	0.0223	CbGpPWpGaD
Conivaptan—AVPR2—brain—acquired immunodeficiency syndrome	0.00253	0.0911	CbGeAlD
Conivaptan—AVPR1A—Peptide ligand-binding receptors—ACKR1—acquired immunodeficiency syndrome	0.00231	0.0203	CbGpPWpGaD
Conivaptan—AVPR2—Peptide ligand-binding receptors—ACKR1—acquired immunodeficiency syndrome	0.00229	0.0201	CbGpPWpGaD
Conivaptan—AVPR1A—Peptide ligand-binding receptors—CCL4—acquired immunodeficiency syndrome	0.00209	0.0183	CbGpPWpGaD
Conivaptan—AVPR2—Peptide ligand-binding receptors—CCL4—acquired immunodeficiency syndrome	0.00207	0.0182	CbGpPWpGaD
Conivaptan—AVPR1A—GPCR ligand binding—CCL3L1—acquired immunodeficiency syndrome	0.00195	0.0171	CbGpPWpGaD
Conivaptan—AVPR2—GPCR ligand binding—CCL3L1—acquired immunodeficiency syndrome	0.00193	0.017	CbGpPWpGaD
Conivaptan—AVPR1A—Peptide GPCRs—CCR5—acquired immunodeficiency syndrome	0.00177	0.0155	CbGpPWpGaD
Conivaptan—AVPR2—Peptide GPCRs—CCR5—acquired immunodeficiency syndrome	0.00175	0.0154	CbGpPWpGaD
Conivaptan—CYP3A4—blood plasma—acquired immunodeficiency syndrome	0.00169	0.061	CbGeAlD
Conivaptan—AVPR1A—Class A/1 (Rhodopsin-like receptors)—ACKR1—acquired immunodeficiency syndrome	0.00155	0.0136	CbGpPWpGaD
Conivaptan—AVPR2—Class A/1 (Rhodopsin-like receptors)—ACKR1—acquired immunodeficiency syndrome	0.00154	0.0135	CbGpPWpGaD
Conivaptan—AVPR1A—Peptide ligand-binding receptors—CCL3—acquired immunodeficiency syndrome	0.00143	0.0125	CbGpPWpGaD
Conivaptan—AVPR2—Peptide ligand-binding receptors—CCL3—acquired immunodeficiency syndrome	0.00142	0.0124	CbGpPWpGaD
Conivaptan—AVPR1A—Class A/1 (Rhodopsin-like receptors)—CCL4—acquired immunodeficiency syndrome	0.0014	0.0123	CbGpPWpGaD
Conivaptan—AVPR2—Class A/1 (Rhodopsin-like receptors)—CCL4—acquired immunodeficiency syndrome	0.00139	0.0122	CbGpPWpGaD
Conivaptan—AVPR1A—Peptide ligand-binding receptors—CCR2—acquired immunodeficiency syndrome	0.00129	0.0113	CbGpPWpGaD
Conivaptan—AVPR2—Peptide ligand-binding receptors—CCR2—acquired immunodeficiency syndrome	0.00128	0.0112	CbGpPWpGaD
Conivaptan—AVPR1A—Peptide ligand-binding receptors—CXCL12—acquired immunodeficiency syndrome	0.00121	0.0106	CbGpPWpGaD
Conivaptan—AVPR1A—Peptide ligand-binding receptors—CXCR4—acquired immunodeficiency syndrome	0.00121	0.0106	CbGpPWpGaD
Conivaptan—AVPR2—Peptide ligand-binding receptors—CXCL12—acquired immunodeficiency syndrome	0.0012	0.0106	CbGpPWpGaD
Conivaptan—AVPR2—Peptide ligand-binding receptors—CXCR4—acquired immunodeficiency syndrome	0.0012	0.0106	CbGpPWpGaD
Conivaptan—AVPR1A—GPCR ligand binding—ACKR1—acquired immunodeficiency syndrome	0.00118	0.0103	CbGpPWpGaD
Conivaptan—AVPR2—GPCR ligand binding—ACKR1—acquired immunodeficiency syndrome	0.00117	0.0103	CbGpPWpGaD
Conivaptan—AVPR1A—GPCR ligand binding—CCL4—acquired immunodeficiency syndrome	0.00107	0.00935	CbGpPWpGaD
Conivaptan—AVPR2—GPCR ligand binding—CCL4—acquired immunodeficiency syndrome	0.00106	0.00929	CbGpPWpGaD
Conivaptan—AVPR1A—GPCRs, Class A Rhodopsin-like—CCR2—acquired immunodeficiency syndrome	0.00101	0.00886	CbGpPWpGaD
Conivaptan—Hyperglycaemia—Delavirdine—acquired immunodeficiency syndrome	0.001	0.00382	CcSEcCtD
Conivaptan—AVPR2—GPCRs, Class A Rhodopsin-like—CCR2—acquired immunodeficiency syndrome	0.001	0.00879	CbGpPWpGaD
Conivaptan—Pneumonia—Delavirdine—acquired immunodeficiency syndrome	0.000999	0.00379	CcSEcCtD
Conivaptan—AVPR1A—Signaling by GPCR—CCL3L1—acquired immunodeficiency syndrome	0.000998	0.00876	CbGpPWpGaD
Conivaptan—Infection—Didanosine—acquired immunodeficiency syndrome	0.000992	0.00377	CcSEcCtD
Conivaptan—AVPR2—Signaling by GPCR—CCL3L1—acquired immunodeficiency syndrome	0.000991	0.0087	CbGpPWpGaD
Conivaptan—Haematuria—Efavirenz—acquired immunodeficiency syndrome	0.000989	0.00376	CcSEcCtD
Conivaptan—Anaemia—Nelfinavir—acquired immunodeficiency syndrome	0.000984	0.00374	CcSEcCtD
Conivaptan—Cardiac disorder—Zidovudine—acquired immunodeficiency syndrome	0.000984	0.00374	CcSEcCtD
Conivaptan—Anaemia—Stavudine—acquired immunodeficiency syndrome	0.000981	0.00373	CcSEcCtD
Conivaptan—Urinary tract disorder—Indinavir—acquired immunodeficiency syndrome	0.000974	0.0037	CcSEcCtD
Conivaptan—Anaemia—Abacavir—acquired immunodeficiency syndrome	0.000967	0.00367	CcSEcCtD
Conivaptan—Urethral disorder—Indinavir—acquired immunodeficiency syndrome	0.000966	0.00367	CcSEcCtD
Conivaptan—Urinary tract infection—Delavirdine—acquired immunodeficiency syndrome	0.000965	0.00367	CcSEcCtD
Conivaptan—AVPR1A—Class A/1 (Rhodopsin-like receptors)—CCL3—acquired immunodeficiency syndrome	0.000956	0.00839	CbGpPWpGaD
Conivaptan—Mediastinal disorder—Zidovudine—acquired immunodeficiency syndrome	0.000955	0.00363	CcSEcCtD
Conivaptan—Pollakiuria—Ritonavir—acquired immunodeficiency syndrome	0.000951	0.00361	CcSEcCtD
Conivaptan—AVPR2—Class A/1 (Rhodopsin-like receptors)—CCL3—acquired immunodeficiency syndrome	0.000949	0.00833	CbGpPWpGaD
Conivaptan—AVPR1A—GPCRs, Class A Rhodopsin-like—CXCR4—acquired immunodeficiency syndrome	0.000949	0.00833	CbGpPWpGaD
Conivaptan—Haematuria—Delavirdine—acquired immunodeficiency syndrome	0.000947	0.0036	CcSEcCtD
Conivaptan—Gastrointestinal disorder—Amprenavir—acquired immunodeficiency syndrome	0.000945	0.00359	CcSEcCtD
Conivaptan—AVPR2—GPCRs, Class A Rhodopsin-like—CXCR4—acquired immunodeficiency syndrome	0.000942	0.00827	CbGpPWpGaD
Conivaptan—Unspecified disorder of skin and subcutaneous tissue—Nevirapine—acquired immunodeficiency syndrome	0.00093	0.00353	CcSEcCtD
Conivaptan—Hyperglycaemia—Ritonavir—acquired immunodeficiency syndrome	0.000929	0.00353	CcSEcCtD
Conivaptan—Mental disorder—Zidovudine—acquired immunodeficiency syndrome	0.000929	0.00353	CcSEcCtD
Conivaptan—Erythema—Zidovudine—acquired immunodeficiency syndrome	0.000923	0.00351	CcSEcCtD
Conivaptan—Malnutrition—Zidovudine—acquired immunodeficiency syndrome	0.000923	0.00351	CcSEcCtD
Conivaptan—AVPR1A—Peptide ligand-binding receptors—CCL5—acquired immunodeficiency syndrome	0.000922	0.00809	CbGpPWpGaD
Conivaptan—Urinary tract disorder—Efavirenz—acquired immunodeficiency syndrome	0.00092	0.00349	CcSEcCtD
Conivaptan—Oedema peripheral—Efavirenz—acquired immunodeficiency syndrome	0.000918	0.00349	CcSEcCtD
Conivaptan—AVPR2—Peptide ligand-binding receptors—CCL5—acquired immunodeficiency syndrome	0.000916	0.00803	CbGpPWpGaD
Conivaptan—Urethral disorder—Efavirenz—acquired immunodeficiency syndrome	0.000913	0.00347	CcSEcCtD
Conivaptan—Unspecified disorder of skin and subcutaneous tissue—Nelfinavir—acquired immunodeficiency syndrome	0.0009	0.00342	CcSEcCtD
Conivaptan—Unspecified disorder of skin and subcutaneous tissue—Stavudine—acquired immunodeficiency syndrome	0.000898	0.00341	CcSEcCtD
Conivaptan—Hyperglycaemia—Saquinavir—acquired immunodeficiency syndrome	0.000894	0.0034	CcSEcCtD
Conivaptan—Urinary tract infection—Ritonavir—acquired immunodeficiency syndrome	0.000892	0.00339	CcSEcCtD
Conivaptan—Pneumonia—Saquinavir—acquired immunodeficiency syndrome	0.000889	0.00338	CcSEcCtD
Conivaptan—Unspecified disorder of skin and subcutaneous tissue—Abacavir—acquired immunodeficiency syndrome	0.000884	0.00336	CcSEcCtD
Conivaptan—Dry mouth—Stavudine—acquired immunodeficiency syndrome	0.000884	0.00336	CcSEcCtD
Conivaptan—Infestation NOS—Saquinavir—acquired immunodeficiency syndrome	0.000884	0.00336	CcSEcCtD
Conivaptan—Infestation—Saquinavir—acquired immunodeficiency syndrome	0.000884	0.00336	CcSEcCtD
Conivaptan—Nervous system disorder—Nevirapine—acquired immunodeficiency syndrome	0.00088	0.00334	CcSEcCtD
Conivaptan—Oedema peripheral—Delavirdine—acquired immunodeficiency syndrome	0.000878	0.00334	CcSEcCtD
Conivaptan—Haematuria—Ritonavir—acquired immunodeficiency syndrome	0.000875	0.00333	CcSEcCtD
Conivaptan—Pollakiuria—Lamivudine—acquired immunodeficiency syndrome	0.000873	0.00332	CcSEcCtD
Conivaptan—Skin disorder—Nevirapine—acquired immunodeficiency syndrome	0.000872	0.00331	CcSEcCtD
Conivaptan—AVPR1A—Class A/1 (Rhodopsin-like receptors)—CCR2—acquired immunodeficiency syndrome	0.000865	0.00759	CbGpPWpGaD
Conivaptan—Cardiac disorder—Efavirenz—acquired immunodeficiency syndrome	0.000864	0.00328	CcSEcCtD
Conivaptan—Urinary tract infection—Saquinavir—acquired immunodeficiency syndrome	0.000859	0.00326	CcSEcCtD
Conivaptan—AVPR2—Class A/1 (Rhodopsin-like receptors)—CCR2—acquired immunodeficiency syndrome	0.000859	0.00753	CbGpPWpGaD
Conivaptan—Malnutrition—Indinavir—acquired immunodeficiency syndrome	0.000858	0.00326	CcSEcCtD
Conivaptan—Pain—Didanosine—acquired immunodeficiency syndrome	0.000854	0.00324	CcSEcCtD
Conivaptan—Anaemia—Zidovudine—acquired immunodeficiency syndrome	0.000853	0.00324	CcSEcCtD
Conivaptan—Hyperglycaemia—Lamivudine—acquired immunodeficiency syndrome	0.000853	0.00324	CcSEcCtD
Conivaptan—Nervous system disorder—Stavudine—acquired immunodeficiency syndrome	0.00085	0.00323	CcSEcCtD
Conivaptan—Infection—Abacavir—acquired immunodeficiency syndrome	0.000848	0.00322	CcSEcCtD
Conivaptan—Angiopathy—Efavirenz—acquired immunodeficiency syndrome	0.000845	0.00321	CcSEcCtD
Conivaptan—Skin disorder—Nelfinavir—acquired immunodeficiency syndrome	0.000844	0.00321	CcSEcCtD
Conivaptan—Skin disorder—Stavudine—acquired immunodeficiency syndrome	0.000842	0.0032	CcSEcCtD
Conivaptan—Mediastinal disorder—Efavirenz—acquired immunodeficiency syndrome	0.000839	0.00319	CcSEcCtD
Conivaptan—Nervous system disorder—Abacavir—acquired immunodeficiency syndrome	0.000837	0.00318	CcSEcCtD
Conivaptan—AVPR1A—Peptide ligand-binding receptors—CCR5—acquired immunodeficiency syndrome	0.000831	0.00729	CbGpPWpGaD
Conivaptan—Skin disorder—Abacavir—acquired immunodeficiency syndrome	0.000829	0.00315	CcSEcCtD
Conivaptan—AVPR2—Peptide ligand-binding receptors—CCR5—acquired immunodeficiency syndrome	0.000825	0.00724	CbGpPWpGaD
Conivaptan—Urinary tract disorder—Ritonavir—acquired immunodeficiency syndrome	0.000814	0.00309	CcSEcCtD
Conivaptan—AVPR1A—Class A/1 (Rhodopsin-like receptors)—CXCL12—acquired immunodeficiency syndrome	0.000813	0.00714	CbGpPWpGaD
Conivaptan—AVPR1A—Class A/1 (Rhodopsin-like receptors)—CXCR4—acquired immunodeficiency syndrome	0.000813	0.00714	CbGpPWpGaD
Conivaptan—Oedema peripheral—Ritonavir—acquired immunodeficiency syndrome	0.000812	0.00308	CcSEcCtD
Conivaptan—Erythema—Efavirenz—acquired immunodeficiency syndrome	0.000811	0.00308	CcSEcCtD
Conivaptan—Malnutrition—Efavirenz—acquired immunodeficiency syndrome	0.000811	0.00308	CcSEcCtD
Conivaptan—Urethral disorder—Ritonavir—acquired immunodeficiency syndrome	0.000808	0.00307	CcSEcCtD
Conivaptan—AVPR2—Class A/1 (Rhodopsin-like receptors)—CXCR4—acquired immunodeficiency syndrome	0.000807	0.00708	CbGpPWpGaD
Conivaptan—AVPR2—Class A/1 (Rhodopsin-like receptors)—CXCL12—acquired immunodeficiency syndrome	0.000807	0.00708	CbGpPWpGaD
Conivaptan—Hypotension—Abacavir—acquired immunodeficiency syndrome	0.000798	0.00303	CcSEcCtD
Conivaptan—Anaemia—Indinavir—acquired immunodeficiency syndrome	0.000793	0.00301	CcSEcCtD
Conivaptan—Body temperature increased—Didanosine—acquired immunodeficiency syndrome	0.000789	0.003	CcSEcCtD
Conivaptan—Insomnia—Nelfinavir—acquired immunodeficiency syndrome	0.000786	0.00299	CcSEcCtD
Conivaptan—Insomnia—Stavudine—acquired immunodeficiency syndrome	0.000784	0.00298	CcSEcCtD
Conivaptan—Urinary tract disorder—Saquinavir—acquired immunodeficiency syndrome	0.000783	0.00298	CcSEcCtD
Conivaptan—Unspecified disorder of skin and subcutaneous tissue—Zidovudine—acquired immunodeficiency syndrome	0.00078	0.00296	CcSEcCtD
Conivaptan—Urethral disorder—Saquinavir—acquired immunodeficiency syndrome	0.000778	0.00295	CcSEcCtD
Conivaptan—Malnutrition—Delavirdine—acquired immunodeficiency syndrome	0.000776	0.00295	CcSEcCtD
Conivaptan—Erythema—Delavirdine—acquired immunodeficiency syndrome	0.000776	0.00295	CcSEcCtD
Conivaptan—Gastrointestinal disorder—Nevirapine—acquired immunodeficiency syndrome	0.000775	0.00294	CcSEcCtD
Conivaptan—Pruritus—Amprenavir—acquired immunodeficiency syndrome	0.000775	0.00294	CcSEcCtD
Conivaptan—Insomnia—Abacavir—acquired immunodeficiency syndrome	0.000772	0.00293	CcSEcCtD
Conivaptan—Pain—Nevirapine—acquired immunodeficiency syndrome	0.000767	0.00292	CcSEcCtD
Conivaptan—Cardiac disorder—Ritonavir—acquired immunodeficiency syndrome	0.000765	0.00291	CcSEcCtD
Conivaptan—Confusional state—Zidovudine—acquired immunodeficiency syndrome	0.000759	0.00288	CcSEcCtD
Conivaptan—Gastrointestinal disorder—Nelfinavir—acquired immunodeficiency syndrome	0.00075	0.00285	CcSEcCtD
Conivaptan—Anaemia—Efavirenz—acquired immunodeficiency syndrome	0.000749	0.00285	CcSEcCtD
Conivaptan—Diarrhoea—Amprenavir—acquired immunodeficiency syndrome	0.000749	0.00285	CcSEcCtD
Conivaptan—Gastrointestinal disorder—Stavudine—acquired immunodeficiency syndrome	0.000748	0.00284	CcSEcCtD
Conivaptan—Angiopathy—Ritonavir—acquired immunodeficiency syndrome	0.000748	0.00284	CcSEcCtD
Conivaptan—Pain—Nelfinavir—acquired immunodeficiency syndrome	0.000743	0.00282	CcSEcCtD
Conivaptan—Mediastinal disorder—Ritonavir—acquired immunodeficiency syndrome	0.000743	0.00282	CcSEcCtD
Conivaptan—Pain—Stavudine—acquired immunodeficiency syndrome	0.000741	0.00281	CcSEcCtD
Conivaptan—Constipation—Stavudine—acquired immunodeficiency syndrome	0.000741	0.00281	CcSEcCtD
Conivaptan—Feeling abnormal—Nevirapine—acquired immunodeficiency syndrome	0.00074	0.00281	CcSEcCtD
Conivaptan—Nervous system disorder—Zidovudine—acquired immunodeficiency syndrome	0.000739	0.00281	CcSEcCtD
Conivaptan—Gastrointestinal disorder—Abacavir—acquired immunodeficiency syndrome	0.000737	0.0028	CcSEcCtD
Conivaptan—Cardiac disorder—Saquinavir—acquired immunodeficiency syndrome	0.000736	0.0028	CcSEcCtD
Conivaptan—Skin disorder—Zidovudine—acquired immunodeficiency syndrome	0.000732	0.00278	CcSEcCtD
Conivaptan—Pain—Abacavir—acquired immunodeficiency syndrome	0.00073	0.00277	CcSEcCtD
Conivaptan—AVPR1A—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	0.000728	0.00639	CbGpPWpGaD
Conivaptan—Unspecified disorder of skin and subcutaneous tissue—Indinavir—acquired immunodeficiency syndrome	0.000726	0.00276	CcSEcCtD
Conivaptan—AVPR2—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	0.000723	0.00634	CbGpPWpGaD
Conivaptan—Mental disorder—Ritonavir—acquired immunodeficiency syndrome	0.000722	0.00274	CcSEcCtD
Conivaptan—Angiopathy—Saquinavir—acquired immunodeficiency syndrome	0.00072	0.00273	CcSEcCtD
Conivaptan—Malnutrition—Ritonavir—acquired immunodeficiency syndrome	0.000717	0.00273	CcSEcCtD
Conivaptan—Anaemia—Delavirdine—acquired immunodeficiency syndrome	0.000717	0.00272	CcSEcCtD
Conivaptan—Feeling abnormal—Nelfinavir—acquired immunodeficiency syndrome	0.000716	0.00272	CcSEcCtD
Conivaptan—Mediastinal disorder—Saquinavir—acquired immunodeficiency syndrome	0.000715	0.00272	CcSEcCtD
Conivaptan—Dry mouth—Indinavir—acquired immunodeficiency syndrome	0.000715	0.00271	CcSEcCtD
Conivaptan—Body temperature increased—Nevirapine—acquired immunodeficiency syndrome	0.000709	0.00269	CcSEcCtD
Conivaptan—Pruritus—Didanosine—acquired immunodeficiency syndrome	0.000706	0.00268	CcSEcCtD
Conivaptan—Feeling abnormal—Abacavir—acquired immunodeficiency syndrome	0.000703	0.00267	CcSEcCtD
Conivaptan—Hypertension—Efavirenz—acquired immunodeficiency syndrome	0.0007	0.00266	CcSEcCtD
Conivaptan—Vomiting—Amprenavir—acquired immunodeficiency syndrome	0.000696	0.00264	CcSEcCtD
Conivaptan—Mental disorder—Saquinavir—acquired immunodeficiency syndrome	0.000695	0.00264	CcSEcCtD
Conivaptan—Malnutrition—Saquinavir—acquired immunodeficiency syndrome	0.000691	0.00262	CcSEcCtD
Conivaptan—Erythema—Saquinavir—acquired immunodeficiency syndrome	0.000691	0.00262	CcSEcCtD
Conivaptan—Body temperature increased—Nelfinavir—acquired immunodeficiency syndrome	0.000687	0.00261	CcSEcCtD
Conivaptan—Nervous system disorder—Indinavir—acquired immunodeficiency syndrome	0.000687	0.00261	CcSEcCtD
Conivaptan—Headache—Amprenavir—acquired immunodeficiency syndrome	0.000686	0.00261	CcSEcCtD
Conivaptan—Unspecified disorder of skin and subcutaneous tissue—Efavirenz—acquired immunodeficiency syndrome	0.000686	0.0026	CcSEcCtD
Conivaptan—Body temperature increased—Stavudine—acquired immunodeficiency syndrome	0.000685	0.0026	CcSEcCtD
Conivaptan—Diarrhoea—Didanosine—acquired immunodeficiency syndrome	0.000683	0.00259	CcSEcCtD
Conivaptan—Mediastinal disorder—Lamivudine—acquired immunodeficiency syndrome	0.000682	0.00259	CcSEcCtD
Conivaptan—Insomnia—Zidovudine—acquired immunodeficiency syndrome	0.000681	0.00259	CcSEcCtD
Conivaptan—Skin disorder—Indinavir—acquired immunodeficiency syndrome	0.00068	0.00258	CcSEcCtD
Conivaptan—Dry mouth—Efavirenz—acquired immunodeficiency syndrome	0.000675	0.00256	CcSEcCtD
Conivaptan—Body temperature increased—Abacavir—acquired immunodeficiency syndrome	0.000675	0.00256	CcSEcCtD
Conivaptan—Hypertension—Delavirdine—acquired immunodeficiency syndrome	0.00067	0.00254	CcSEcCtD
Conivaptan—Confusional state—Efavirenz—acquired immunodeficiency syndrome	0.000667	0.00253	CcSEcCtD
Conivaptan—Anaemia—Ritonavir—acquired immunodeficiency syndrome	0.000663	0.00252	CcSEcCtD
Conivaptan—Erythema—Lamivudine—acquired immunodeficiency syndrome	0.000659	0.0025	CcSEcCtD
Conivaptan—Malnutrition—Lamivudine—acquired immunodeficiency syndrome	0.000659	0.0025	CcSEcCtD
Conivaptan—AVPR1A—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	0.000659	0.00578	CbGpPWpGaD
Conivaptan—AVPR2—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	0.000654	0.00574	CbGpPWpGaD
Conivaptan—CYP3A4—digestive system—acquired immunodeficiency syndrome	0.000651	0.0235	CbGeAlD
Conivaptan—AVPR1A—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	0.00065	0.00571	CbGpPWpGaD
Conivaptan—Nausea—Amprenavir—acquired immunodeficiency syndrome	0.00065	0.00247	CcSEcCtD
Conivaptan—Gastrointestinal disorder—Zidovudine—acquired immunodeficiency syndrome	0.00065	0.00247	CcSEcCtD
Conivaptan—Nervous system disorder—Efavirenz—acquired immunodeficiency syndrome	0.000649	0.00247	CcSEcCtD
Conivaptan—Dry mouth—Delavirdine—acquired immunodeficiency syndrome	0.000646	0.00245	CcSEcCtD
Conivaptan—AVPR2—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	0.000646	0.00567	CbGpPWpGaD
Conivaptan—Constipation—Zidovudine—acquired immunodeficiency syndrome	0.000644	0.00245	CcSEcCtD
Conivaptan—Pain—Zidovudine—acquired immunodeficiency syndrome	0.000644	0.00245	CcSEcCtD
Conivaptan—Skin disorder—Efavirenz—acquired immunodeficiency syndrome	0.000643	0.00244	CcSEcCtD
Conivaptan—Confusional state—Delavirdine—acquired immunodeficiency syndrome	0.000638	0.00243	CcSEcCtD
Conivaptan—Anaemia—Saquinavir—acquired immunodeficiency syndrome	0.000638	0.00242	CcSEcCtD
Conivaptan—Pruritus—Nevirapine—acquired immunodeficiency syndrome	0.000635	0.00241	CcSEcCtD
Conivaptan—Vomiting—Didanosine—acquired immunodeficiency syndrome	0.000635	0.00241	CcSEcCtD
Conivaptan—Insomnia—Indinavir—acquired immunodeficiency syndrome	0.000634	0.00241	CcSEcCtD
Conivaptan—Infection—Delavirdine—acquired immunodeficiency syndrome	0.000629	0.00239	CcSEcCtD
Conivaptan—Headache—Didanosine—acquired immunodeficiency syndrome	0.000625	0.00238	CcSEcCtD
Conivaptan—Feeling abnormal—Zidovudine—acquired immunodeficiency syndrome	0.000621	0.00236	CcSEcCtD
Conivaptan—CYP3A4—blood—acquired immunodeficiency syndrome	0.00062	0.0224	CbGeAlD
Conivaptan—Hypertension—Ritonavir—acquired immunodeficiency syndrome	0.000619	0.00235	CcSEcCtD
Conivaptan—AVPR1A—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	0.000619	0.00543	CbGpPWpGaD
Conivaptan—AVPR1A—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	0.000619	0.00543	CbGpPWpGaD
Conivaptan—AVPR1A—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	0.000619	0.00543	CbGpPWpGaD
Conivaptan—Skin disorder—Delavirdine—acquired immunodeficiency syndrome	0.000615	0.00234	CcSEcCtD
Conivaptan—Pruritus—Nelfinavir—acquired immunodeficiency syndrome	0.000615	0.00234	CcSEcCtD
Conivaptan—AVPR2—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	0.000615	0.00539	CbGpPWpGaD
Conivaptan—AVPR2—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	0.000615	0.00539	CbGpPWpGaD
Conivaptan—AVPR2—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	0.000614	0.00539	CbGpPWpGaD
Conivaptan—Diarrhoea—Nevirapine—acquired immunodeficiency syndrome	0.000614	0.00233	CcSEcCtD
Conivaptan—Pruritus—Stavudine—acquired immunodeficiency syndrome	0.000613	0.00233	CcSEcCtD
Conivaptan—Anaemia—Lamivudine—acquired immunodeficiency syndrome	0.000609	0.00231	CcSEcCtD
Conivaptan—Unspecified disorder of skin and subcutaneous tissue—Ritonavir—acquired immunodeficiency syndrome	0.000607	0.0023	CcSEcCtD
Conivaptan—AVPR1A—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	0.000605	0.00531	CbGpPWpGaD
Conivaptan—Gastrointestinal disorder—Indinavir—acquired immunodeficiency syndrome	0.000605	0.0023	CcSEcCtD
Conivaptan—Pruritus—Abacavir—acquired immunodeficiency syndrome	0.000604	0.00229	CcSEcCtD
Conivaptan—AVPR2—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	0.000601	0.00527	CbGpPWpGaD
Conivaptan—Pain—Indinavir—acquired immunodeficiency syndrome	0.000599	0.00228	CcSEcCtD
Conivaptan—Constipation—Indinavir—acquired immunodeficiency syndrome	0.000599	0.00228	CcSEcCtD
Conivaptan—Insomnia—Efavirenz—acquired immunodeficiency syndrome	0.000599	0.00227	CcSEcCtD
Conivaptan—Dry mouth—Ritonavir—acquired immunodeficiency syndrome	0.000597	0.00227	CcSEcCtD
Conivaptan—Hypertension—Saquinavir—acquired immunodeficiency syndrome	0.000596	0.00226	CcSEcCtD
Conivaptan—Body temperature increased—Zidovudine—acquired immunodeficiency syndrome	0.000595	0.00226	CcSEcCtD
Conivaptan—Diarrhoea—Nelfinavir—acquired immunodeficiency syndrome	0.000595	0.00226	CcSEcCtD
Conivaptan—Diarrhoea—Stavudine—acquired immunodeficiency syndrome	0.000593	0.00225	CcSEcCtD
Conivaptan—Nausea—Didanosine—acquired immunodeficiency syndrome	0.000593	0.00225	CcSEcCtD
Conivaptan—Hypotension—Delavirdine—acquired immunodeficiency syndrome	0.000592	0.00225	CcSEcCtD
Conivaptan—Confusional state—Ritonavir—acquired immunodeficiency syndrome	0.00059	0.00224	CcSEcCtD
Conivaptan—AVPR1A—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	0.00059	0.00518	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	0.000586	0.00514	CbGpPWpGaD
Conivaptan—Diarrhoea—Abacavir—acquired immunodeficiency syndrome	0.000584	0.00222	CcSEcCtD
Conivaptan—Unspecified disorder of skin and subcutaneous tissue—Saquinavir—acquired immunodeficiency syndrome	0.000584	0.00222	CcSEcCtD
Conivaptan—Feeling abnormal—Indinavir—acquired immunodeficiency syndrome	0.000577	0.00219	CcSEcCtD
Conivaptan—Dry mouth—Saquinavir—acquired immunodeficiency syndrome	0.000575	0.00218	CcSEcCtD
Conivaptan—Nervous system disorder—Ritonavir—acquired immunodeficiency syndrome	0.000574	0.00218	CcSEcCtD
Conivaptan—Insomnia—Delavirdine—acquired immunodeficiency syndrome	0.000573	0.00218	CcSEcCtD
Conivaptan—Gastrointestinal disorder—Efavirenz—acquired immunodeficiency syndrome	0.000571	0.00217	CcSEcCtD
Conivaptan—Vomiting—Nevirapine—acquired immunodeficiency syndrome	0.000571	0.00217	CcSEcCtD
Conivaptan—Skin disorder—Ritonavir—acquired immunodeficiency syndrome	0.000569	0.00216	CcSEcCtD
Conivaptan—Confusional state—Saquinavir—acquired immunodeficiency syndrome	0.000568	0.00216	CcSEcCtD
Conivaptan—Constipation—Efavirenz—acquired immunodeficiency syndrome	0.000566	0.00215	CcSEcCtD
Conivaptan—Pain—Efavirenz—acquired immunodeficiency syndrome	0.000566	0.00215	CcSEcCtD
Conivaptan—Headache—Nevirapine—acquired immunodeficiency syndrome	0.000562	0.00214	CcSEcCtD
Conivaptan—Infection—Saquinavir—acquired immunodeficiency syndrome	0.00056	0.00213	CcSEcCtD
Conivaptan—AVPR1A—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	0.000557	0.00489	CbGpPWpGaD
Conivaptan—Unspecified disorder of skin and subcutaneous tissue—Lamivudine—acquired immunodeficiency syndrome	0.000557	0.00212	CcSEcCtD
Conivaptan—Body temperature increased—Indinavir—acquired immunodeficiency syndrome	0.000554	0.0021	CcSEcCtD
Conivaptan—AVPR2—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	0.000553	0.00486	CbGpPWpGaD
Conivaptan—Nervous system disorder—Saquinavir—acquired immunodeficiency syndrome	0.000553	0.0021	CcSEcCtD
Conivaptan—Vomiting—Nelfinavir—acquired immunodeficiency syndrome	0.000553	0.0021	CcSEcCtD
Conivaptan—Vomiting—Stavudine—acquired immunodeficiency syndrome	0.000551	0.00209	CcSEcCtD
Conivaptan—Dry mouth—Lamivudine—acquired immunodeficiency syndrome	0.000548	0.00208	CcSEcCtD
Conivaptan—Skin disorder—Saquinavir—acquired immunodeficiency syndrome	0.000547	0.00208	CcSEcCtD
Conivaptan—Hypotension—Ritonavir—acquired immunodeficiency syndrome	0.000547	0.00208	CcSEcCtD
Conivaptan—AVPR1A—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	0.000547	0.0048	CbGpPWpGaD
Conivaptan—Gastrointestinal disorder—Delavirdine—acquired immunodeficiency syndrome	0.000547	0.00208	CcSEcCtD
Conivaptan—Feeling abnormal—Efavirenz—acquired immunodeficiency syndrome	0.000545	0.00207	CcSEcCtD
Conivaptan—Headache—Nelfinavir—acquired immunodeficiency syndrome	0.000545	0.00207	CcSEcCtD
Conivaptan—AVPR2—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	0.000543	0.00477	CbGpPWpGaD
Conivaptan—Headache—Stavudine—acquired immunodeficiency syndrome	0.000543	0.00206	CcSEcCtD
Conivaptan—Vomiting—Abacavir—acquired immunodeficiency syndrome	0.000543	0.00206	CcSEcCtD
Conivaptan—Confusional state—Lamivudine—acquired immunodeficiency syndrome	0.000542	0.00206	CcSEcCtD
Conivaptan—Pain—Delavirdine—acquired immunodeficiency syndrome	0.000541	0.00206	CcSEcCtD
Conivaptan—Constipation—Delavirdine—acquired immunodeficiency syndrome	0.000541	0.00206	CcSEcCtD
Conivaptan—Headache—Abacavir—acquired immunodeficiency syndrome	0.000535	0.00203	CcSEcCtD
Conivaptan—Infection—Lamivudine—acquired immunodeficiency syndrome	0.000534	0.00203	CcSEcCtD
Conivaptan—Nausea—Nevirapine—acquired immunodeficiency syndrome	0.000533	0.00202	CcSEcCtD
Conivaptan—Pruritus—Zidovudine—acquired immunodeficiency syndrome	0.000533	0.00202	CcSEcCtD
Conivaptan—Insomnia—Ritonavir—acquired immunodeficiency syndrome	0.00053	0.00201	CcSEcCtD
Conivaptan—Nervous system disorder—Lamivudine—acquired immunodeficiency syndrome	0.000527	0.002	CcSEcCtD
Conivaptan—Hypotension—Saquinavir—acquired immunodeficiency syndrome	0.000527	0.002	CcSEcCtD
Conivaptan—Body temperature increased—Efavirenz—acquired immunodeficiency syndrome	0.000523	0.00199	CcSEcCtD
Conivaptan—Skin disorder—Lamivudine—acquired immunodeficiency syndrome	0.000522	0.00198	CcSEcCtD
Conivaptan—Feeling abnormal—Delavirdine—acquired immunodeficiency syndrome	0.000522	0.00198	CcSEcCtD
Conivaptan—Nausea—Nelfinavir—acquired immunodeficiency syndrome	0.000516	0.00196	CcSEcCtD
Conivaptan—Diarrhoea—Zidovudine—acquired immunodeficiency syndrome	0.000515	0.00196	CcSEcCtD
Conivaptan—Nausea—Stavudine—acquired immunodeficiency syndrome	0.000515	0.00196	CcSEcCtD
Conivaptan—Insomnia—Saquinavir—acquired immunodeficiency syndrome	0.00051	0.00194	CcSEcCtD
Conivaptan—Nausea—Abacavir—acquired immunodeficiency syndrome	0.000507	0.00193	CcSEcCtD
Conivaptan—Gastrointestinal disorder—Ritonavir—acquired immunodeficiency syndrome	0.000506	0.00192	CcSEcCtD
Conivaptan—CYP3A4—nervous system—acquired immunodeficiency syndrome	0.000503	0.0181	CbGeAlD
Conivaptan—Hypotension—Lamivudine—acquired immunodeficiency syndrome	0.000502	0.00191	CcSEcCtD
Conivaptan—Pain—Ritonavir—acquired immunodeficiency syndrome	0.000501	0.0019	CcSEcCtD
Conivaptan—Constipation—Ritonavir—acquired immunodeficiency syndrome	0.000501	0.0019	CcSEcCtD
Conivaptan—Body temperature increased—Delavirdine—acquired immunodeficiency syndrome	0.000501	0.0019	CcSEcCtD
Conivaptan—Pruritus—Indinavir—acquired immunodeficiency syndrome	0.000496	0.00188	CcSEcCtD
Conivaptan—Gastrointestinal disorder—Saquinavir—acquired immunodeficiency syndrome	0.000487	0.00185	CcSEcCtD
Conivaptan—Insomnia—Lamivudine—acquired immunodeficiency syndrome	0.000486	0.00185	CcSEcCtD
Conivaptan—CYP3A4—central nervous system—acquired immunodeficiency syndrome	0.000485	0.0175	CbGeAlD
Conivaptan—Feeling abnormal—Ritonavir—acquired immunodeficiency syndrome	0.000483	0.00183	CcSEcCtD
Conivaptan—Pain—Saquinavir—acquired immunodeficiency syndrome	0.000482	0.00183	CcSEcCtD
Conivaptan—Constipation—Saquinavir—acquired immunodeficiency syndrome	0.000482	0.00183	CcSEcCtD
Conivaptan—Diarrhoea—Indinavir—acquired immunodeficiency syndrome	0.000479	0.00182	CcSEcCtD
Conivaptan—Vomiting—Zidovudine—acquired immunodeficiency syndrome	0.000479	0.00182	CcSEcCtD
Conivaptan—Headache—Zidovudine—acquired immunodeficiency syndrome	0.000472	0.00179	CcSEcCtD
Conivaptan—AVPR1A—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	0.000471	0.00413	CbGpPWpGaD
Conivaptan—Pruritus—Efavirenz—acquired immunodeficiency syndrome	0.000468	0.00178	CcSEcCtD
Conivaptan—AVPR2—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	0.000468	0.0041	CbGpPWpGaD
Conivaptan—Feeling abnormal—Saquinavir—acquired immunodeficiency syndrome	0.000464	0.00176	CcSEcCtD
Conivaptan—Gastrointestinal disorder—Lamivudine—acquired immunodeficiency syndrome	0.000464	0.00176	CcSEcCtD
Conivaptan—Body temperature increased—Ritonavir—acquired immunodeficiency syndrome	0.000463	0.00176	CcSEcCtD
Conivaptan—Constipation—Lamivudine—acquired immunodeficiency syndrome	0.00046	0.00175	CcSEcCtD
Conivaptan—Pain—Lamivudine—acquired immunodeficiency syndrome	0.00046	0.00175	CcSEcCtD
Conivaptan—Diarrhoea—Efavirenz—acquired immunodeficiency syndrome	0.000453	0.00172	CcSEcCtD
Conivaptan—Pruritus—Delavirdine—acquired immunodeficiency syndrome	0.000448	0.0017	CcSEcCtD
Conivaptan—Nausea—Zidovudine—acquired immunodeficiency syndrome	0.000447	0.0017	CcSEcCtD
Conivaptan—Body temperature increased—Saquinavir—acquired immunodeficiency syndrome	0.000446	0.00169	CcSEcCtD
Conivaptan—Vomiting—Indinavir—acquired immunodeficiency syndrome	0.000445	0.00169	CcSEcCtD
Conivaptan—Feeling abnormal—Lamivudine—acquired immunodeficiency syndrome	0.000443	0.00168	CcSEcCtD
Conivaptan—Headache—Indinavir—acquired immunodeficiency syndrome	0.000439	0.00167	CcSEcCtD
Conivaptan—Diarrhoea—Delavirdine—acquired immunodeficiency syndrome	0.000433	0.00165	CcSEcCtD
Conivaptan—Body temperature increased—Lamivudine—acquired immunodeficiency syndrome	0.000425	0.00161	CcSEcCtD
Conivaptan—AVPR1A—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	0.000424	0.00372	CbGpPWpGaD
Conivaptan—AVPR2—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	0.000421	0.0037	CbGpPWpGaD
Conivaptan—Vomiting—Efavirenz—acquired immunodeficiency syndrome	0.000421	0.0016	CcSEcCtD
Conivaptan—Nausea—Indinavir—acquired immunodeficiency syndrome	0.000416	0.00158	CcSEcCtD
Conivaptan—Headache—Efavirenz—acquired immunodeficiency syndrome	0.000415	0.00157	CcSEcCtD
Conivaptan—Pruritus—Ritonavir—acquired immunodeficiency syndrome	0.000414	0.00157	CcSEcCtD
Conivaptan—Vomiting—Delavirdine—acquired immunodeficiency syndrome	0.000403	0.00153	CcSEcCtD
Conivaptan—Diarrhoea—Ritonavir—acquired immunodeficiency syndrome	0.000401	0.00152	CcSEcCtD
Conivaptan—Pruritus—Saquinavir—acquired immunodeficiency syndrome	0.000399	0.00151	CcSEcCtD
Conivaptan—Headache—Delavirdine—acquired immunodeficiency syndrome	0.000397	0.00151	CcSEcCtD
Conivaptan—Nausea—Efavirenz—acquired immunodeficiency syndrome	0.000393	0.00149	CcSEcCtD
Conivaptan—Diarrhoea—Saquinavir—acquired immunodeficiency syndrome	0.000386	0.00146	CcSEcCtD
Conivaptan—Pruritus—Lamivudine—acquired immunodeficiency syndrome	0.00038	0.00144	CcSEcCtD
Conivaptan—Nausea—Delavirdine—acquired immunodeficiency syndrome	0.000376	0.00143	CcSEcCtD
Conivaptan—AVPR1A—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	0.000374	0.00328	CbGpPWpGaD
Conivaptan—Vomiting—Ritonavir—acquired immunodeficiency syndrome	0.000372	0.00141	CcSEcCtD
Conivaptan—AVPR1A—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	0.000372	0.00327	CbGpPWpGaD
Conivaptan—AVPR2—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	0.000371	0.00326	CbGpPWpGaD
Conivaptan—AVPR2—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	0.000369	0.00324	CbGpPWpGaD
Conivaptan—Diarrhoea—Lamivudine—acquired immunodeficiency syndrome	0.000368	0.0014	CcSEcCtD
Conivaptan—Headache—Ritonavir—acquired immunodeficiency syndrome	0.000367	0.00139	CcSEcCtD
Conivaptan—Vomiting—Saquinavir—acquired immunodeficiency syndrome	0.000358	0.00136	CcSEcCtD
Conivaptan—AVPR1A—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	0.000357	0.00314	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	0.000357	0.00314	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	0.000355	0.00311	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	0.000355	0.00311	CbGpPWpGaD
Conivaptan—Headache—Saquinavir—acquired immunodeficiency syndrome	0.000353	0.00134	CcSEcCtD
Conivaptan—AVPR1A—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	0.00035	0.00307	CbGpPWpGaD
Conivaptan—AVPR1A—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	0.00035	0.00307	CbGpPWpGaD
Conivaptan—Nausea—Ritonavir—acquired immunodeficiency syndrome	0.000348	0.00132	CcSEcCtD
Conivaptan—AVPR2—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	0.000347	0.00305	CbGpPWpGaD
Conivaptan—AVPR2—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	0.000347	0.00305	CbGpPWpGaD
Conivaptan—Vomiting—Lamivudine—acquired immunodeficiency syndrome	0.000342	0.0013	CcSEcCtD
Conivaptan—AVPR1A—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	0.000338	0.00297	CbGpPWpGaD
Conivaptan—Headache—Lamivudine—acquired immunodeficiency syndrome	0.000337	0.00128	CcSEcCtD
Conivaptan—AVPR2—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	0.000336	0.00294	CbGpPWpGaD
Conivaptan—Nausea—Saquinavir—acquired immunodeficiency syndrome	0.000335	0.00127	CcSEcCtD
Conivaptan—AVPR1A—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	0.000323	0.00284	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	0.000321	0.00282	CbGpPWpGaD
Conivaptan—Nausea—Lamivudine—acquired immunodeficiency syndrome	0.000319	0.00121	CcSEcCtD
Conivaptan—AVPR1A—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	0.000318	0.00279	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	0.000318	0.00279	CbGpPWpGaD
Conivaptan—AVPR2—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	0.000315	0.00277	CbGpPWpGaD
Conivaptan—AVPR2—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	0.000315	0.00277	CbGpPWpGaD
Conivaptan—AVPR1A—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	0.000266	0.00234	CbGpPWpGaD
Conivaptan—AVPR2—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	0.000264	0.00232	CbGpPWpGaD
Conivaptan—AVPR1A—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	0.000262	0.0023	CbGpPWpGaD
Conivaptan—AVPR2—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	0.00026	0.00228	CbGpPWpGaD
Conivaptan—AVPR1A—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—acquired immunodeficiency syndrome	0.000256	0.00224	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	0.000242	0.00212	CbGpPWpGaD
Conivaptan—AVPR2—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	0.00024	0.00211	CbGpPWpGaD
Conivaptan—AVPR1A—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	0.00024	0.0021	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	0.000238	0.00209	CbGpPWpGaD
Conivaptan—AVPR2—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	0.000238	0.00209	CbGpPWpGaD
Conivaptan—AVPR2—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	0.000236	0.00207	CbGpPWpGaD
Conivaptan—AVPR2—Transmembrane transport of small molecules—ALB—acquired immunodeficiency syndrome	0.000232	0.00204	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	0.000221	0.00194	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	0.000219	0.00192	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	0.000218	0.00191	CbGpPWpGaD
Conivaptan—AVPR2—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	0.000216	0.0019	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	0.0002	0.00175	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	0.000198	0.00174	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	0.000188	0.00165	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	0.000188	0.00165	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	0.000186	0.00164	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	0.000186	0.00164	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	0.000143	0.00125	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	0.000142	0.00124	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	0.000141	0.00123	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	0.00014	0.00123	CbGpPWpGaD
Conivaptan—AVPR1A—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	0.000139	0.00122	CbGpPWpGaD
Conivaptan—AVPR2—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	0.000138	0.00121	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	0.000129	0.00113	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	0.000128	0.00112	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	0.000126	0.0011	CbGpPWpGaD
Conivaptan—AVPR2—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	0.000125	0.0011	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—IL2—acquired immunodeficiency syndrome	7.43e-05	0.000652	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	7.4e-05	0.000649	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—IL2—acquired immunodeficiency syndrome	7.38e-05	0.000648	CbGpPWpGaD
Conivaptan—AVPR2—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	7.34e-05	0.000644	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—TAT—acquired immunodeficiency syndrome	7.33e-05	0.000643	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—AGPS—acquired immunodeficiency syndrome	6.23e-05	0.000547	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—IL6—acquired immunodeficiency syndrome	4.37e-05	0.000383	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—IL6—acquired immunodeficiency syndrome	4.34e-05	0.000381	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—ALB—acquired immunodeficiency syndrome	1.28e-05	0.000112	CbGpPWpGaD
